TABLE 4.
The relationship between SIRI scores and molecular breast cancer subtype.
| Parameters | N | SIRI 785 | N | SIRI 477 | N | SIRI 308 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n) | 785 | Low SIRI 484 | High SIRI 301 | χ2 | p value | Low SIRI 267 | High SIRI 210 | χ2 | p value | Low SIRI 217 | High SIRI 91 | χ2 | p value | ||
| Core needle biopsy (N = 477) | |||||||||||||||
| Molecular subtype | 3.520 | 0.475 | |||||||||||||
| Luminal A | 25 (5.24%) | 15 (5.62%) | 10 (4.76%) | ||||||||||||
| Luminal B HER2+ | 67 (14.05%) | 31 (11.61%) | 36 (17.14%) | ||||||||||||
| Luminal B HER2- | 186 (38.99%) | 105 (39.33%) | 81 (38.57%) | ||||||||||||
| HER2 enriched | 91 (19.08%) | 51 (19.10%) | 40 (19.05%) | ||||||||||||
| Triple negative | 108 (22.64%) | 65 (24.34%) | 43 (20.48%) | ||||||||||||
| ER status | 0.042 | 0.838 | |||||||||||||
| Negative | 191 (40.04%) | 108 (40.45%) | 83 (39.52%) | ||||||||||||
| Positive | 286 (59.96%) | 159 (59.55%) | 127 (60.48%) | ||||||||||||
| ER status | 0.929 | 0.920 | |||||||||||||
| 0–25% | 228 (47.80%) | 129 (48.31%) | 99 (47.14%) | ||||||||||||
| 26–50% | 42 (8.81%) | 26 (9.74%) | 16 (7.62%) | ||||||||||||
| 51–75% | 33 (6.92%) | 18 (6.74%) | 15 (7.14%) | ||||||||||||
| 76–100% | 174 (36.48%) | 94 (35.21%) | 80 (38.10%) | ||||||||||||
| PR status | 0.964 | 0.326 | |||||||||||||
| Negative | 189 (39.62%) | 111 (41.57%) | 78 (37.14%) | ||||||||||||
| Positive | 288 (60.38%) | 156 (58.43%) | 132 (62.86%) | ||||||||||||
| PR status | 2.467 | 0.651 | |||||||||||||
| 0–25% | 286 (59.96%) | 165 (61.80%) | 121 (57.62%) | ||||||||||||
| 26–50% | 67 (14.05%) | 35 (13.11%) | 32 (15.24%) | ||||||||||||
| 51–75% | 45 (9.43%) | 21 (7.87%) | 24 (11.43%) | ||||||||||||
| 76–100% | 79 (16.56%) | 46 (17.23%) | 33 (15.71%) | ||||||||||||
| HER2 status | 1.743 | 0.187 | |||||||||||||
| Negative (0--++) | 313 (65.62%) | 182 (68.16%) | 131 (62.38%) | ||||||||||||
| Positive (+++) | 164 (34.38%) | 85 (31.84%) | 79 (37.62%) | ||||||||||||
| Ki-67 status | 1.455 | 0.118 | |||||||||||||
| Negative (≤14%) | 84 (17.61%) | 52 (19.48%) | 32 (15.24%) | ||||||||||||
| Positive (>14%) | 393 (82.39%) | 215 (80.52%) | 178 (84.76%) | ||||||||||||
| Ki-67 status | 1.218 | 0.875 | |||||||||||||
| 0–25% | 161 (33.75%) | 92 (34.46%) | 69 (32.86%) | ||||||||||||
| 26–50% | 189 (39.62%) | 109 (40.82%) | 80 (38.10%) | ||||||||||||
| 51–75% | 88 (18.45%) | 45 (16.85%) | 43 (20.48%) | ||||||||||||
| 76–100% | 39 (8.18%) | 21 (7.87%) | 18 (8.57%) | ||||||||||||
| Postoperative pathology (IHC) | |||||||||||||||
| Molecular subtype | 8.634 | 0.125 | 5.449 | 0.364 | 12.370 | 0.030 | |||||||||
| Luminal A | 62 (7.90%) | 41 (8.47%) | 21 (6.98%) | 41 (8.60%) | 22 (8.24%) | 19 (9.05%) | 21 (6.82%) | 19 (8.76%) | 2 (2.20%) | ||||||
| Luminal B HER2+ | 98 (12.48%) | 52 (10.74%) | 46 (15.28%) | 61 (12.79%) | 28 (10.49%) | 33 (15.71%) | 37 (12.01%) | 24 (11.06%) | 13 (14.29%) | ||||||
| Luminal B HER2- | 325 (41.40%) | 211 (43.60%) | 114 (37.87%) | 166 (34.80%) | 96 (35.96%) | 70 (33.33%) | 159 (51.62%) | 115 (53.00%) | 44 (48.35%) | ||||||
| HER2 enriched | 129 (16.43%) | 70 (14.46%) | 59 (19.60%) | 96 (20.13%) | 53 (19.85%) | 43 (20.48%) | 33 (10.71%) | 17 (7.83%) | 16 (17.58%) | ||||||
| Triple negative | 171 (21.78%) | 110 (22.73%) | 61 (20.27%) | 113 (23.69%) | 68 (25.47%) | 45 (21.43%) | 58 (18.83%) | 42 (19.35%) | 16 (17.58%) | ||||||
| ER status | 0.465 | 0.495 | 0.286 | 0.593 | 1.884 | 0.170 | |||||||||
| Negative | 296 (37.71%) | 178 (36.78%) | 118 (39.20%) | 195 (40.88%) | 112 (41.95%) | 83 (39.52%) | 101 (32.79%) | 66 (30.41%) | 35 (38.46%) | ||||||
| Positive | 489 (62.29%) | 306 (63.22%) | 183 (60.80%) | 282 (59.12%) | 155 (58.05%) | 127 (60.48%) | 207 (67.21%) | 151 (69.59%) | 56 (61.54%) | ||||||
| ER status | 3.061 | 0.548 | 0.530 | 0.971 | 6.402 | 0.171 | |||||||||
| 0–25% | 375 (47.77%) | 232 (47.93%) | 143 (47.51%) | 235 (49.27%) | 134 (50.19%) | 101 (48.10%) | 140 (45.45%) | 98 (45.16%) | 42 (46.15%) | ||||||
| 26–50% | 66 (8.41%) | 41 (8.47%) | 25 (8.31%) | 31 (6.50%) | 16 (5.99%) | 15 (7.14%) | 35 (11.36%) | 25 (11.52%) | 10 (10.99%) | ||||||
| 51–75% | 48 (6.11%) | 24 (4.96%) | 24 (7.97%) | 27 (5.66%) | 14 (5.24%) | 13 (6.19%) | 21 (6.82%) | 10 (4.61%) | 11 (12.09%) | ||||||
| 76–100% | 296 (37.71%) | 187 (38.64%) | 109 (36.21%) | 184 (38.57%) | 103 (38.58%) | 81 (38.57%) | 112 (36.36%) | 84 (38.71%) | 28 (30.77%) | ||||||
| PR status | 1.168 | 0.280 | 0.007 | 0.933 | 1.720 | 0.190 | |||||||||
| Negative | 315 (40.13%) | 187 (38.64%) | 128 (42.52%) | 210 (44.03%) | 118 (44.19%) | 92 (43.81%) | 105 (34.09%) | 69 (31.80%) | 36 (39.56%) | ||||||
| Positive | 470 (59.87%) | 297 (61.36%) | 173 (57.48%) | 267 (55.97%) | 149 (55.81%) | 118 (56.19%) | 203 (65.91%) | 148 (68.20%) | 55 (60.44%) | ||||||
| PR status | 6.924 | 0.140 | 1.764 | 0.779 | 2.296 | 0.682 | |||||||||
| 0–25% | 502 (63.95%) | 301 (62.19%) | 201 (66.78%) | 335 (70.23%) | 187 (70.04%) | 148 (70.48%) | 167 (54.22%) | 114 (52.53%) | 53 (58.24%) | ||||||
| 26–50% | 90 (11.46%) | 57 (11.78%) | 33 (10.96%) | 48 (10.06%) | 28 (10.49%) | 20 (9.52%) | 42 (13.64%) | 29 (13.36%) | 13 (14.29%) | ||||||
| 51–75% | 55 (7.01%) | 29 (5.99%) | 26 (8.64%) | 38 (7.97%) | 18(6.74%) | 20 (9.52%) | 17 (5.52%) | 11 (5.07%) | 6 (6.59%) | ||||||
| 76–100% | 138 (17.58%) | 97 (20.04%) | 41 (13.62%) | 56 (11.74%) | 34 (12.73%) | 22 (10.48%) | 82 (26.62%) | 63 (29.03%) | 19 (20.88%) | ||||||
| HER2 status | 8.077 | 0.005 | 1.824 | 0.177 | 5.660 | 0.017 | |||||||||
| Negative (0--++) | 557 (70.96%) | 361 (74.59%) | 196 (65.12%) | 320 (67.09%) | 186 (69.66%) | 134 (63.81%) | 237 (76.95%) | 175 (80.65%) | 62 (68.13%) | ||||||
| Positive (+++) | 228 (29.04%) | 123 (25.41%) | 105 (34.88%) | 157 (32.91%) | 81 (30.34%) | 76 (36.19%) | 71 (23.05%) | 42 (19.35%) | 29 (31.87%) | ||||||
| Ki-67 status | 0.423 | 0.516 | 0.072 | 0.788 | 2.802 | 0.094 | |||||||||
| Negative (≤14%) | 219 (27.90%) | 139 (28.72%) | 80 (26.58%) | 153 (32.08%) | 87 (32.58%) | 66 (31.43%) | 66 (21.43%) | 52 (23.96%) | 14 (15.38%) | ||||||
| Positive (>14%) | 566 (72.10%) | 345 (71.28%) | 221 (73.42%) | 324 (67.92%) | 180 (67.42%) | 144 (68.57%) | 242 (78.57%) | 165 (76.04%) | 77 (84.62%) | ||||||
| Ki-67 status | 5.107 | 0.277 | 4.227 | 0.376 | 1.436 | 0.838 | |||||||||
| 0–25% | 342 (43.57%) | 215 (44.42%) | 127 (42.19%) | 233 (48.85%) | 134 (50.19%) | 99 (47.14%) | 109 (35.39%) | 81 (37.33%) | 28 (30.77%) | ||||||
| 26–50% | 257 (32.74%) | 163 (33.68%) | 94 (31.23%) | 139 (29.14%) | 81 (30.34%) | 58 (27.62%) | 118 (38.31%) | 82 (37.79%) | 36 (39.56%) | ||||||
| 51–75% | 137 (17.45%) | 83 (17.15%) | 54 (17.94%) | 70 (14.68%) | 38 (14.23%) | 32 (15.24%) | 67 (21.75%) | 45 (20.74%) | 22 (24.18%) | ||||||
| 76–100% | 49 (6.24%) | 23 (4.75%) | 26 (8.64%) | 35 (7.34%) | 14 (5.24%) | 21 (10.00%) | 14 (4.55%) | 9 (4.15%) | 5 (5.49%) | ||||||
| AR status | 1.209 | 0.272 | 0.018 | 0.892 | 0.040 | 0.841 | |||||||||
| Negative | 666 (84.84%) | 416 (85.95%) | 250 (83.06%) | 362 (75.89%) | 202 (75.66%) | 160 (76.19%) | 304 (98.70%) | 214 (98.62%) | 90 (98.90%) | ||||||
| Positive | 119 (15.16%) | 68 (14.05%) | 51 (16.94%) | 115 (24.11%) | 65 (24.34%) | 50 (23.81%) | 4 (1.30%) | 3 (1.38%) | 1 (1.10%) | ||||||
| AR status | 1.665 | 0.797 | 3.144 | 0.534 | 0.021 | 0.885 | |||||||||
| 0–25% | 688 (87.64%) | 424 (87.60%) | 264 (87.71%) | 383 (80.29%) | 209 (78.28%) | 174 (82.86%) | 305 (99.03%) | 215 (99.08%) | 90 (98.90%) | ||||||
| 26–50% | 25 (3.18%) | 13 (2.69%) | 12 (3.99%) | 25 (5.24%) | 13 (4.87%) | 12 (5.71%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| 51–75% | 29 (3.69%) | 20 (4.13%) | 9 (2.99%) | 29 (6.08%) | 20 (7.49%) | 9 (4.29%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| 76–100% | 43 (5.48%) | 27 (5.58%) | 16 (5.32%) | 40 (8.39%) | 25 (9.36%) | 15 (7.14%) | 3 (0.97%) | 2 (0.92%) | 1 (1.10%) | ||||||
| CK5/6 status | 1.336 | 0.248 | 0.940 | 0.332 | 0.003 | 0.954 | |||||||||
| Negative | 684 (87.13%) | 427 (88.22%) | 257 (85.38%) | 406 (85.12%) | 231 (86.52%) | 175 (83.33%) | 278 (90.26%) | 196 (90.32%) | 82 (90.11%) | ||||||
| Positive | 101 (12.87%) | 57 (11.78%) | 44 (14.62%) | 71 (14.88%) | 36 (13.48%) | 35 (16.67%) | 30 (9.74%) | 21 (9.68%) | 9 (9.89%) | ||||||
| E-cad status | 21.406 | <0.0001 | 3.593 | 0.058 | 14.686 | 0.0001 | |||||||||
| Negative | 353 (44.97%) | 249 (51.45%) | 104 (34.55%) | 170 (35.64%) | 105 (39.33%) | 65 (30.95%) | 183 (59.42%) | 144 (66.36%) | 39 (42.86%) | ||||||
| Positive | 432 (55.03%) | 235 (48.55%) | 197 (65.45%) | 307 (64.36%) | 162 (60.67%) | 145 (69.05%) | 125 (40.58%) | 73 (33.64%) | 52 (57.14%) | ||||||
| EGFR status | 6.339 | 0.012 | 0.494 | 0.482 | 6.983 | 0.008 | |||||||||
| Negative | 589 (75.03%) | 378 (78.10%) | 211 (70.10%) | 335 (70.23%) | 191 (71.54%) | 144 (68.57%) | 254 (82.47%) | 187 (86.18%) | 67 (73.63%) | ||||||
| Positive | 196 (24.97%) | 106 (21.90%) | 90 (29.90%) | 142 (29.77%) | 76 (28.46%) | 66 (31.43%) | 54 (17.53%) | 30 (13.82%) | 24 (26.37%) | ||||||
| P53 status | 0.642 | 0.423 | 0.303 | 0.582 | 0.528 | 0.467 | |||||||||
| Negative | 395 (50.32%) | 249 (51.45%) | 146 (48.50%) | 243 (50.94%) | 139 (52.06%) | 104 (49.52%) | 152 (49.35%) | 110 (50.69%) | 42 (46.15%) | ||||||
| Positive | 390 (49.68%) | 235 (48.55%) | 155 (51.50%) | 234 (49.06%) | 128 (47.94%) | 106 (50.48%) | 156 (50.65%) | 107 (49.31%) | 49 (53.85%) | ||||||
| P53 status | 1.755 | 0.781 | 3.412 | 0.491 | 0.082 | 0.960 | |||||||||
| 0–25% | 576 (73.38%) | 362 (74.79%) | 214 (71.10%) | 353 (74.00%) | 204 (76.40%) | 149 (70.95%) | 223 (72.40%) | 158 (72.81%) | 65 (71.43%) | ||||||
| 26–50% | 80 (10.19%) | 49 (10.12%) | 31 (10.30%) | 45 (9.43%) | 25 (9.36%) | 20 (9.52%) | 35 (11.36%) | 24 (11.06%) | 11 (12.09%) | ||||||
| 51–75% | 108 (13.76%) | 61 (12.60%) | 47 (15.61%) | 58 (12.16%) | 26 (9.74%) | 32 (15.24%) | 50 (16.23%) | 35 (16.13%) | 15 (16.48%) | ||||||
| 76–100% | 21 (2.68%) | 12 (2.48%) | 9 (2.99%) | 21 (4.40%) | 12 (4.49%) | 9 (4.29%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| TOP2A status | 5.595 | 0.018 | 0.101 | 0.750 | 8.526 | 0.004 | |||||||||
| Negative | 299 (38.09%) | 200 (41.32%) | 99 (32.89%) | 165 (34.59%) | 94 (35.21%) | 71 (33.81%) | 134 (43.51%) | 106 (48.85%) | 28 (30.77%) | ||||||
| Positive | 486 (61.91%) | 284 (58.68%) | 202 (67.11%) | 312 (65.41%) | 173 (64.79%) | 139 (66.19%) | 174 (56.49%) | 111 (51.15%) | 63 (69.23%) | ||||||
| TOP2A status | 4.005 | 0.405 | 1.690 | 0.793 | 15.817 | 0.003 | |||||||||
| 0–25% | 575 (73.25%) | 366 (75.62%) | 209 (69.44%) | 354 (74.21%) | 200 (74.91%) | 154 (73.33%) | 221 (71.75%) | 166 (76.50%) | 55 (60.44%) | ||||||
| 26–50% | 158 (20.13%) | 90 (18.60%) | 68 (22.59%) | 88 (18.45%) | 45 (16.85%) | 43 (20.48%) | 70 (22.73%) | 45 (20.74%) | 25 (27.47%) | ||||||
| 51–75% | 49 (6.24%) | 26 (5.37%) | 23 (7.64%) | 33 (6.92%) | 21 (7.87%) | 12 (5.71%) | 16 (5.19%) | 5 (2.30%) | 11 (12.09%) | ||||||
| 76–100% | 3 (0.38%) | 2 (0.41%) | 1 (0.33%) | 2 (0.42%) | 1 (0.37%) | 1 (0.48%) | 1 (0.32%) | 1 (0.46%) | 0 (0.00%) | ||||||
| Lymph vessel invasion | 4.403 | 0.036 | 0.048 | 0.826 | 11.377 | 0.001 | |||||||||
| Negative | 558 (71.08%) | 357 (73.76%) | 201 (66.78%) | 320 (67.09%) | 178 (66.67%) | 142 (67.62%) | 238 (77.27%) | 179 (82.49%) | 59 (64.84%) | ||||||
| Positive | 227 (28.92%) | 127 (26.24%) | 100 (33.22%) | 157 (32.91%) | 89 (33.33%) | 68 (32.38%) | 70 (22.73%) | 38 (17.51%) | 32 (35.16%) | ||||||
| Neural invasion | 0.0004 | 0.984 | 0.470 | 0.493 | 0.059 | 0.808 | |||||||||
| Negative | 670 (85.35%) | 413 (85.33%) | 257 (85.38%) | 384 (80.50%) | 212 (79.40%) | 172 (81.90%) | 286 (92.86%) | 201 (92.63%) | 85 (93.41%) | ||||||
| Positive | 115 (14.65%) | 71 (14.67%) | 44 (14.62%) | 93 (19.50%) | 55 (20.60%) | 38 (18.10%) | 22 (7.14%) | 16 (7.37%) | 6 (6.59%) | ||||||